Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:DYN 7 October 2025 - 4 January 2026

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

TuHURA Biosciences plunged 36.9% after announcing a $15.6 million direct offering with warrants, triggering heavy dilution concerns. Phreesia, Euda Health, SLM Corp, Virgin Galactic, and Gogo each fell more than 15%. Major indexes stayed mostly flat, with the Dow up 0.2% and the S&P 500 up 0.1% as traders awaited the Federal Reserve’s policy decision.
9 December 2025
··········
Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics shares jumped 14% to $23.20 by mid-afternoon Monday after the company reported its Phase 1/2 DELIVER trial in Duchenne muscular dystrophy met its primary endpoint. The stock touched an intraday high near $25.68 on volume over 2.5 million shares. Dyne plans to seek U.S. accelerated approval in 2026. The company reported $792 million in cash as of Q3 2025.
8 December 2025
·
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics shares jumped over 10% to around $14 after new trial data showed its lead therapy improved muscle function with no serious side effects. The stock is up about 75% in six months. Dyne’s Duchenne drug just received Orphan Drug status in Japan and positive analyst upgrades, with price targets averaging $34. The company ended June with $683.9 million in cash, extending its runway into 2027.
7 October 2025
·
Go toTop